Cargando…
Management of hepatocellular carcinoma in the time of COVID-19
Autores principales: | Iavarone, M., Sangiovanni, A., Carrafiello, G., Rossi, G., Lampertico, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172712/ https://www.ncbi.nlm.nih.gov/pubmed/32330540 http://dx.doi.org/10.1016/j.annonc.2020.04.007 |
Ejemplares similares
-
Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC
por: Biondetti, Pierpaolo, et al.
Publicado: (2021) -
An Unprecedented Challenge: The North Italian Gastroenterologist Response to COVID-19
por: Tontini, Gian Eugenio, et al.
Publicado: (2021) -
Reply to: Correspondence on “High rates of 30-day mortality in patients with cirrhosis and COVID-19”
por: Iavarone, Massimo, et al.
Publicado: (2020) -
Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis
por: Sangiovanni, Angelo, et al.
Publicado: (2021) -
PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma
por: Valenti, Luca, et al.
Publicado: (2013)